Photo: Dwight Eschliman/Getty Images

It's too soon to throw in the towel on biosimilars, especially because there's evidence that they're lowering the net costs of biologics, Alex Brill and Benedic Ippolito of the American Enterprise Institute argue in a Health Affairs blog.

Why it matters: The authors were refuting an April post in Health Affairs that argued biologics are a natural monopoly, so biosimilars aren't going to work.

What they're saying: The number of biosimilars in development is increasing, and two biologics facing biosimilar competition — Neupogen and Remicade — have begun offering bigger discounts to stay competitive, even though their list prices haven't come down.

The bottom line: "Although prices likely will not reach close to marginal costs ... this does not imply that biologics, writ large, are natural monopolies in any traditional sense of the concept," Brill and Ippolito write.

  • The big question going forward, Ippolito told me, is how low biologic prices will go.

Go deeper: How to jump-start a fledgling class of new, cheaper drugs

Go deeper

Biden's big economic plan plays it down the middle for Democrats

Illustration: Aïda Amer/Axios

Joe Biden yesterday laid out the broad strokes of his economic policy platform, which seemingly is designed to not freak out centrists and not piss off progressives.

Why it matters: Biden has a better-than-even shot of becoming the next president, which means his tax plans could become everyone's tax bills.

Coronavirus surge punctures oil's recovery

Illustration: Aïda Amer/Axios

The growth of coronavirus cases is "casting a shadow" over oil's recovery despite the partial demand revival and supply cuts that have considerably tightened the market in recent months, the International Energy Agency said Friday.

Why it matters: IEA's monthly report confirms what analysts have seen coming for a long time: Failure to contain the virus is a huge threat to the market rebound that has seen prices grow, but remain at a perilous level for many companies.

3 hours ago - Sports

Big Ten's conference-only move could spur a regionalized college sports season

Illustration: Aïda Amer/Axios

The Big Ten announced Thursday that it will move all fall sports to a conference-only schedule.

Why it matters: This will have a snowball effect on the rest of the country, and could force all Power 5 conferences to follow suit, resulting in a regionalized fall sports season.